Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HER-2 (c-erbB-2) test update: present status and problems.

Hitoshi Tsuda1

  • 1Department of Pathology II, National Defense Medical College, Japan. htsuda@ndmc.ac.jp.

Breast Cancer (Tokyo, Japan)
|August 25, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nationwide survey of hereditary breast and ovarian cancer-related clinical practice in gynecologic oncology in Japan: a joint study by the Japan Society of Gynecologic Oncology (JSGO) and the Japan Society of Obstetrics and Gynecology (JSOG).

Journal of gynecologic oncology·2026
Same author

A simple morphometric algorithm based on nuclear atypia features of invasive breast carcinoma: relationship with nuclear grade, Ki-67 level, and hormone receptor status.

Breast cancer (Tokyo, Japan)·2026
Same author

Multicenter ex vivo evaluation of an α-mannosidase-targeted fluorescent probe for intraoperative margin assessment in breast cancer.

Scientific reports·2026
Same author

Radiofrequency Ablation for Early Stage Breast Cancer as a Potential Alternative to Partial Mastectomy: 5-Year Results from the Multiple-Center, Single-Arm, Phase 3 RAFAELO Study (NCCH1409).

Annals of surgical oncology·2026
Same author

Overexpression of JMJD6 drives immune evasion via the BRD4-IRF1-PD-L1 axis and promotes malignancy in gastric cancer.

Scientific reports·2025
Same author

AI-driven spatial mapping of myxoid stroma and tumor-infiltrating lymphocytes in esophageal squamous cell carcinoma.

Esophagus : official journal of the Japan Esophageal Society·2025

HER-2 testing identifies breast cancer patients who may benefit from trastuzumab therapy. Accurate HER-2 assessment via immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) is crucial for treatment decisions and prognosis.

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Cancer Biomarkers

Background:

  • HER-2 (Human Epidermal growth factor Receptor 2) overexpression is a key factor in breast cancer progression and treatment response.
  • Trastuzumab (Herceptin) is a targeted therapy effective for HER-2-positive metastatic breast cancer.
  • HER-2 status is increasingly recognized as a prognostic indicator for recurrence risk in both node-negative and node-positive breast cancers.

Purpose of the Study:

  • To review the established and emerging roles of HER-2 testing in breast cancer management.
  • To discuss the recommended methodologies for HER-2 assessment, including immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).
  • To emphasize the critical importance of quality control in HER-2 testing for accurate clinical application.

Main Methods:

Related Experiment Videos

  • Review of recent clinical data and consensus guidelines regarding HER-2 testing in breast cancer.
  • Discussion of the diagnostic algorithms involving immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).
  • Emphasis on adherence to standardized protocols and robust quality control measures.

Main Results:

  • Convincing data support trastuzumab efficacy in neoadjuvant and adjuvant settings for HER-2-positive primary breast cancer.
  • HER-2 protein overexpression or gene amplification is an established indicator of higher recurrence risk.
  • The consensus favors a sequential testing approach: IHC first, followed by FISH for uncertain results, though alternative strategies exist.

Conclusions:

  • Accurate HER-2 testing is essential for patient selection for trastuzumab therapy and for risk stratification.
  • Standardized testing protocols and stringent quality control (internal and external) are paramount for reliable HER-2 assessment.
  • HER-2 testing plays a vital role in both routine diagnosis and clinical research for breast cancer.